Martina B. Hautmann

  • Citations Per Year
Learn More
The goal of the present study was to determine the molecular mechanism whereby transforming growth factor b (TGFb) increases smooth muscle (SM) a-actin expression. Confluent, growth-arrested rat aortic smooth muscle cells (SMC) were transiently transfected with various SM a-actin promoter/chloramphenicol acetyltransferase deletion mutants and stimulated(More)
Transforming growth factor-b (TGF-b) has been shown to stimulate smooth muscle (SM) a-actin expression in smooth muscle cells (SMCs) and non-SMCs. We previously demonstrated that the 2 CArG boxes A and B and a novel TGF-b control element (TCE) located within the first 125 bp of the SM a-actin promoter were required for TGF-b inducibility of SM a-actin in(More)
AIM The aim of our comprehensive single centre analysis was to evaluate the incidence of coronary heart disease (CHD) in extremely obese patients. METHODS AND RESULTS Between 2005 and 2015 we investigated retrospectively 23,359 patients undergoing cardiac catheterisation in our institution. Patients were divided in six weight classes according to World(More)
BACKGROUND Functional mitral regurgitation (FMR) is common in patients with advanced heart failure and impaired left ventricular function. The study aim was to examine functional and hemodynamic effects at three months after MitraClip® implantation in high-risk surgical patients with FMR. METHODS A group of 93 patients was rejected for surgical treatment(More)
An adenoviral construct encoding a nuclear-localized β-galactosidase marker protein was injected into the heart of chick embryos at Hamburger-Hamilton (HH) stage 14–15 (approximately 52–56 h of incubation). Reporter gene expression was determined 48–54 h after injection. Efficient gene transfer into endothelial cells (ECs) of intraembryonic and yolk sac(More)
BACKGROUND Clinically silent brain injury detected with cerebral magnetic resonance imaging (MRI) is well known after various cardiovascular interventions. Thus far, only one study has examined the periprocedural risk of cerebral ischemic events in patients undergoing percutaneous mitral valve reconstruction. The study aim was to examine the incidence and(More)
OBJECTIVES This study sought to investigate whether the percutaneous mitral regurgitation (MR) reduction with the MitraClip® system in end-stage heart failure patients with a left ventricular ejection fraction (LVEF) of <20% also effects beneficial outcome or whether the underlying myogenic problem is leading and therefore of prognostic relevance. (More)
OBJECTIVES We sought to determine the effects of experience on the Mitraclip® procedure steps as well as procedure safety and functional results. BACKGROUND MR has proven deleterious in heart failure. Mitraclip® therapy evolved an important option in patients with severely reduced left ventricular function (LVEF). METHODS Between 2011 and 2016, 126(More)
  • 1